Running head: ORAL DEXTROSE GEL IN THE TREATMENT OF NH

Oral Dextrose Gel in the Treatment of Neonatal Hypoglycemia:
An Evidence Based Practice Change
Sylvia Cruz
Arizona State University

1

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

2

Abstract
Neonatal hypoglycemia (NH) is a common concern among term and late preterm infants in the
first day of life. Current NH management follows the American Academy of Pediatrics’
guideline to treat with intravenous dextrose if blood sugar levels fall below a set threshold, which
in many cases requires admission to the neonatal intensive care unit (NICU). Oral dextrose gel is
currently an effective, inexpensive, and safe treatment for hypoglycemia in the pediatric and
adult population, and researchers are exploring its use in the neonatal population. This prompted
the following research question: in otherwise healthy late preterm and term newborns at risk for
NH, how does the use of oral dextrose gel in addition to oral feedings, as compared to the current
standard of care of oral feedings alone, affect blood sugar homeostasis in the first day of life? To
answer this research question, upon completing a review of the literature and obtaining IRB
approval on site, an evidence based practice change was implemented that included the addition
of oral dextrose gel to the existing NH protocol in a tertiary hospital in the southwestern United
States with a level III NICU and a busy delivery service.
Keywords: neonatal hypoglycemia treatment, neonatal hypoglycemia oral dextrose gel,
neonatal blood glucose homeostasis, neonatal hypoglycemia management, neonatal glucose
metabolism, oral dextrose gel versus intravenous dextrose, neonatal hypoglycemia protocol

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

3

Oral Dextrose Gel in the Treatment of Neonatal Hypoglycemia
Neonatal hypoglycemia (NH) is a common problem in the newborn period that usually
resolves on its own in the first few days of life. Not all infants who have low blood sugar levels
are symptomatic; therefore many hospitals have NH protocols that screen infants based on risk
factors. Infants with critically low blood glucose levels defined as <30mg/dL, if left untreated for
a prolonged period of time, can have significantly impaired motor and mental development at 18
months of age, although current research has yet to determine the blood glucose level and
duration threshold at which this irreversible damage occurs.
Background & Significance
Neonatal hypoglycemia is the leading cause for NICU admissions among late preterm
and term infants (Bennett, Headtke, & Rowe-Telow, 2015). It is commonly seen in otherwise
healthy newborns by one to two hours of life, and is often asymptomatic and transient with blood
glucose levels as low as 30mg/dL. While NH is considered a normal part of transition to extrauterine life that usually resolves by the first day of life, in some infants blood glucose
homeostasis takes longer regardless of the infant being asymptomatic and feeding well.
Historically, treatment has followed the American Academy of Pediatrics’ (AAP)
recommendation to feed the infant and recheck blood glucose in one hour (Committee on Fetus
and Newborn & Adamkin, 2011). If the repeat blood glucose is less than 25mg/dL despite oral
feeding, the infant will require treatment with IV dextrose, which means that the infant will be
admitted to the NICU for treatment. Not only does this separation interfere with maternal-infant
interaction in the first day of life, it can also lead to decreased breastfeeding rates (Bennett et al.,
2015). Many existing hospital NH protocols specify blood glucose screening procedures, and if
after a specified amount of time the infant’s blood glucose remains out of range despite feeding

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

4

well and being asymptomatic, the AAP recommends IV dextrose administration even though a
blood glucose level of 45mg/dL on the first day of life is not nearly as significant for
neurological damage as on the third day of life, where the blood sugar levels should be greater
than 70mg/dL on average (Brown & Rozance, 2016).
Problem Statement
Persistent NH, when left untreated, has been linked to poor neurological outcomes such
as seizures, learning deficits, cerebral palsy and mental retardation (Bennett, Fagan,
Chaharbakhshi, Zamfirova, & Flicker, 2016). It is estimated that 15% of otherwise healthy
newborns are affected by neonatal hypoglycemia (Mosalli, 2014). Certain factors place newborn
infants at a higher risk of developing hypoglycemia in the first day of life, and those risk factors
include being born to a diabetic mother (IDM), late prematurity (34-37 weeks gestation), post
maturity (> 41 weeks gestation), small for gestational age (less than the 10th percentile in weight
for gestational age), large for gestational age (greater than the 90th percentile in weight for
gestational age), and other reasons after birth such as poor feeding (Harris, Weston, & Harding,
2012).
According to the March of Dimes Perinatal Data Center (2011), 19% of special care
nursery (SCN) or neonatal intensive care (NICU) admissions were late preterm infants (34-37
weeks gestation) with hospital length of stay (LOS) ranging from 5.9 to 9.8 days. Nearly six
percent of late preterm infants admitted to SCN or NICU units had the admitting diagnosis of
NH, and no other complications that required them to be in the NICU for treatment. In the
facility where this evidence based practice change was implemented, 49 infants who were
otherwise healthy were admitted to the NICU for NH treatment in 2017 alone.

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

5

It is estimated that the hospital cost for a NICU stay for NH for an otherwise healthy late
preterm or term infant can range from $37,137 to $51,083 (March of Dimes Perinatal Data
Center, 2011). A regular newborn nursery admission for a healthy late preterm or term newborn
is estimated to be only $4415 (Rawat et al., 2016). In the facility where this evidence based
practice change was implemented, the cost of caring for these 49 infants who were otherwise
healthy could be estimated to be around 2.5 million dollars in 2017. This prompted the following
PICOT question: in otherwise healthy late preterm and term newborns at risk for NH, how does
the use of oral dextrose gel in addition to oral feedings, as compared to the current standard of
care of oral feedings alone, affect blood sugar homeostasis in the first day of life?
Search Strategy
In order to answer the aforementioned PICOT question, the following databases were
searched: The Cochrane Library, PubMed, Cumulative Index of Nursing and Allied Health
Literature (CINAHL), and ASU Libraries OneSearch. Keywords included: neonatal
hypoglycemia, neonatal hypoglycaemia, neonatal hypoglycemia treatment, neonatal
hypoglycemia oral dextrose gel, neonatal blood glucose homeostasis, neonatal hypoglycemia
management, neonatal glucose metabolism, oral dextrose gel versus intravenous dextrose,
neonatal hypoglycemia protocol. Both American and English spellings of keywords were used.
Filters were set to include research articles with publication dates within the last five years. The
strategy also included ancestral searching and reviews of gray literature to determine the overall
incidence of NH and to identify differences in NH incidence related to different risk factors, in
addition to different treatment strategies for NH.
The initial search for “neonatal hypoglycaemia” in the Cochrane Library yielded 196
articles. When the search was limited to “neonatal hypoglycaemia AND treatment”, the results

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

6

were narrowed down to 159 articles. A further limitation to only include “neonatal
hypoglycaemia AND dextrose gel” resulted in 16 articles. After close examination, only one
systematic review in the Cochrane Library was applicable to this project’s topic and retained for
further review (Appendix A).
PubMed was searched using the keywords “neonatal hypoglycemia management”, which
resulted in 714 possible articles. After adding additional limits to only include articles from the
most recent five years and peer-reviewed articles, while changing the search terms to “neonatal
hypoglycemia oral dextrose gel” the search yielded seven articles, all of which were retained for
further review (Appendix B).
A search using CINAHL using the key words “neonatal hypoglycemia treatment” yielded
11 results that were published within the past five years. After adding additional filters for peer
reviewed articles and research, one article remained. A separate CINAHL keyword search using
“neonatal hypoglycemia oral dextrose gel” yielded two articles, and both were retained for
review (Appendix C).
Lastly, ASULibraries OneSearch was used with the following keywords “neonatal
hypoglycemia oral dextrose”. Limitations that were added were publication date within past five
years and scholarly and peer-reviewed journal articles. This yielded 146 articles, however, the
majority of the articles focused on gestational diabetes and implications for pregnant women
rather than hypoglycemia in the neonatal population (Appendix D).
Eleven final articles were selected for critical appraisal: one systematic review, six
randomized controlled trials, and four retrospective chart reviews.
Evidence Synthesis

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

7

While a review of the literature confirms that there is no specific plasma glucose
concentration or duration of NH that can predict permanent neurological injury in at risk infants,
the treatment for asymptomatic hypoglycemic newborns in the first day of life is up for debate
(Committee on Fetus and Newborn & Adamkin, 2011). Until recently, NH has been treated by
IV dextrose administration as recommended by the AAP (Bennett et al., 2016), but recent
literature reviews show that oral dextrose gel is being investigated as a possible alternative
treatment for NH.
A retrospective chart review pre- and post-implementation of oral dextrose gel in an NH
treatment trial found that the primary admitting diagnosis to the NICU for NH decreased from a
mean of 11% to 2% (Bennett et al., 2015). In a follow up study led by Bennett et al. (2016), the
researchers found that using oral dextrose gel in addition to oral feeding reduced NICU
admissions significantly for otherwise healthy newborns with transient NH. During a 14-month
period, they noted a continued decrease in NICU admissions for NH among late preterm and
term infants (Bennett et al., 2016).
Brown and Rozance (2016) noted that while in their study oral dextrose gel appeared to
be effective in treating NH in asymptomatic term infants, they felt the same results likely would
not apply to infants with symptomatic or severe NH. Their concern was that using oral dextrose
gel in symptomatic infants might delay treatment with IV dextrose and lead to irreversible
neurological damage (Brown & Rozance, 2016).
Harding et al. (2015) designed a randomized, placebo controlled trial that proposed the
prevention of NH by giving oral dextrose gel to infants who are at risk for NH but are not
currently experiencing low blood sugar levels. In a follow up study led by Hegarty et al. (2016),

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

8

prophylactic use of oral dextrose gel in at risk newborns resulted in fewer NICU admissions for
NH compared to the placebo group.
The Sugar Babies Study, a randomized, double blind, placebo-controlled trial done in
New Zealand, found that the addition of oral dextrose gel to oral feeding reduced the frequency
of NH treatment failure leading to NICU admission for IV dextrose administration, as compared
with placebo (Harris et al., 2013).
Another study found that 51% of term and late preterm infants who were considered to be
at risk for developing NH in the first day of life became hypoglycemic, with 19% developing
severe NH (Harris, Weston, & Harding, 2012). While this particular study did not discuss the use
of oral dextrose gel as a possible non-invasive and alternative treatment for NH, the findings did
underline the importance of routine screening protocols for at risk infants, as these infants are at
significantly higher risk for developing NH especially when multiple risk factors are present.
Harris et al. (2012) then used the findings of this study in subsequent research that specifically
looked at the use of oral dextrose gel in NH treatment and prevention.
A Cochrane review led by Weston et al. (2016) found that the use of 40% oral dextrose
gel reduced NICU admissions for NH and also reduced the frequency of mother-baby separation
for NH treatment. The Cochrane review found no evidence of adverse effects of oral dextrose
use during the neonatal period or at two years of age (Weston et al., 2016).
Mosalli (2014) found that at risk infants treated with oral dextrose gel were nearly twice
as likely to achieve blood glucose homeostasis without needing additional interventions such as
IV dextrose, as compared to their counterparts who received a placebo gel.
Another study led by Rawat et al. (2016) found that oral dextrose gel increased blood
glucose levels in 74% of their study group, which led to reduced NICU admissions for IV

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

9

dextrose treatment. They also noted that exclusive breastfeeding rates improved from 19% to
28% (Rawat et al., 2016).
While the use of oral dextrose gel may be an innovative and inexpensive solution to a
long existing problem in the NICU, it is also important to note that there should be specific
guidelines in place by what measure NH is diagnosed. Ly, Alexander, Akinmboni, Woo, and
Driscoll (2016) set out to improve the diagnosis of NH by comparing point of care glucose
(POCG) measurements with serum glucose measurements. What they found was that POCG
measurements can vary greatly in accuracy, especially if blood glucose levels are below normal.
If NH is suspected after a low POCG measurement, a confirmatory serum glucose test needs to
be done to prevent delay in treatment (Ly et al., 2016). While the researchers could not
determine a blood glucose threshold that would warrant immediate treatment besides oral
feeding for an asymptomatic hypoglycemic newborn as the normal physiologic nadir is
suspected to be around 30mg/dL, many hospital policies follow the AAP’s guideline to intervene
at a blood glucose level <40mg/dL (Ly et al., 2016).
Recent studies are pointing towards oral dextrose gel being a safe, inexpensive, and noninvasive alternative to the traditional IV dextrose treatment for NH for late preterm and term
infants who otherwise have no other health concerns that would require treatment in the NICU. If
indeed effective in helping achieve blood glucose homeostasis in the first day of life, not only
could the inclusion of oral dextrose gel in existing NH policies potentially reduce unnecessary
NICU admissions, it could also improve exclusive breastfeeding rates which is a Joint
Commission perinatal core measure.

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

10

Purpose Statement
The purpose of this evidence based practice change is to add oral dextrose gel to the
existing NH protocol as a safe, effective, and alternative treatment for NH, as compared to the
previous standard of care in this particular setting where infants were admitted to the NICU to
receive treatment with IV dextrose if oral feedings alone were not effective at achieving blood
glucose homeostasis within a set time frame. This practice change will benefit the hospital by
reducing healthcare costs associated with NICU admissions, and will also benefit infants and
their families by shortening their hospital length of stay and therefore reduce associated
healthcare expenses and by not separating the mother-infant dyad.
Evidence Based Practice Model
The model chosen to guide the application of the synthesized evidence is the Model for
Evidence-Based Practice Change (Rosswurm & Larrabee, 1999). This model illustrates the
process for implementing research evidence into clinical practice in six specific steps (Appendix
E). The first step is identification of a clinical issue, collecting internal and external data, and
involving stakeholders. Research evidence supporting the proposed practice change was
presented to the nursing research council, pediatricians, neonatologists, neonatal nurse
practitioners, and hospital leadership.
The second step is to do a literature search to locate the best evidence. Step three is to
critically analyze the evidence found in step two. The fourth step is to define practice change,
and design a protocol. Using data from the literature search, an updated NH protocol was created
that included an NH algorithm that outlined the steps nurses would take to identify infants at risk
for NH and when to administer oral dextrose gel and the frequency of blood glucose checks.

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

11

The fifth step is implementation of the new protocol and evaluating the study. Evaluation of the
study included comparing data of 27 infants post-implementation of the practice change who met
risk factors for NH to 27 infants pre-implementation of the practice change. Care was taken to
ensure that both groups had similar birth weights, gestational ages, risk factors, and initial blood
glucose values to ensure a homogenous sample. Collecting data from a controlled setting such as
one hospital will help determine the effectiveness of the evidence-based protocol, and using this
model will allow for either modification or implementation of a practice protocol (Melnyk &
Fineout-Overholt, 2015). Once the fifth step is finalized and conclusions and recommendations
have been made, the final step is to maintain the change in practice, and to implement the change
at other hospitals in the same system.
Theoretical Model
The theoretical model that guided this project was Lewin’s Theory of Planned Change.
Lewin’s change theory describes the process of effectively implementing change as a simple
three-step process. Using Lewin’s Theory of Planned Change, the first step is identifying a
problem (Shirey, 2013). The problem of NH treatment was identified and staff who would be
taking care of infants that would qualify to receive oral dextrose gel were included in education
about the practice change. This ensured staff readiness for the change.
The second stage of Lewin’s change theory looks at change as a process rather than an
event (Shirey, 2013). In cooperation with hospital educators, the researcher ensured that staff
was ready for the change, had a protocol in place, and implemented the practice change.
The third and last stage of Lewin’s theory is refreezing the change (Shirey, 2013). What
this entails is ensuring that the change is sustained to continually improve outcomes. This was
achieved by keeping communication lines open with the education department and staff, to

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

12

ensure that if there were any concerns they would be able to voice those concerns freely to
ensure staff support throughout the practice change. Upon completion of this project, the results
will be shared with the hospital staff and nursing research committee.
Project Methods
Human subjects protection was obtained by the researcher from the hospital and
university IRB prior to implementing the practice change. The researcher created an updated NH
protocol along with an NH algorithm (Appendix F) that was displayed in multiple areas for easy
reference. Nursing education was delivered via a voice-over PowerPoint created by the
researcher and approved by the hospital nursing research committee to ensure consistency in the
delivery of educational materials. This PowerPoint remains available on the hospital’s intranet
and nurses providing care for infants in labor and delivery, newborn nursery, postpartum, and
NICU were all educated on the use of the new algorithm. Questions regarding the new protocol
were answered by the researcher directly to ensure consistency. Instruments used to obtain blood
glucose levels were bedside glucometers that were maintained by the hospital laboratory staff
following manufacturer recommendation, and nursing staff performed quality control tests daily.
Data collection included chart reviews of 27 infants with similar inclusion criteria who received
IV dextrose as treatment for NH in the previous year, and 27 infants post-implementation of the
new protocol who met risk factors and/or received oral dextrose gel as initial treatment for NH.
All statistical analysis was performed using SPSS v.24 (IBM Corp, 2016).
Project Results
Upon data collection of 54 infants with similar demographical information, statistical
analysis was performed to determine that this was a homogenous sample. While the gestational
age range for this project included infants born at 34 weeks to greater than 41 weeks, both the

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

13

pre-implementation group and post-implementation group had similar gestational age means, 37
2⁄ (SD=1.8) and 37 5⁄ (SD=2) respectively. Additionally, birth weights in both groups ranged
7
7
from 1630 gram to 5060 gram, with the mean birth weight in the pre-implementation group at
3392 gram (SD=892) and in the post-implementation group 3056 gram (SD=697). Using a t-test,
no statistically significant differences were identified between both groups’ demographics.
While none of the infants in the pre-implementation group received oral dextrose gel for
NH treatment, all 27 infants in this group received IV dextrose infusion as treatment at a
standard rate of 200mg/kg which is identical to the oral dextrose gel dose of 200mg/kg. Because
the infants in this group all received IV dextrose this group has a 100% NICU admission rate. In
the post-implementation group, 24 out of 27 infants received oral dextrose gel. While seven
infants in the post-implementation group were admitted to the NICU for NH, chart reviews
revealed that only two of those infants were admitted for NH and not other diagnoses that
required admission to the NICU. This means that in the post-implementation group, the NICU
admission rate for NH is 9% with a p<0.001 which indicates statistical significance.
The clinical significance of the two infants who received oral dextrose gel and were
admitted to the NICU for treatment with IV dextrose is that they likely experienced refractory
hypoglycemia secondary to being IDM, suggesting the possibility of hyperinsulinism, which
complicates NH.
Discussion
Upon data analysis, results will be presented to the nursing research committee to be
shared with nursing staff. This project will be sustained in the hospital as it is evidence based
practice, but slight modifications to the protocol will be made based on the results of this study,
such as changing the post term age ranges to greater than 42 weeks (currently set at >41 weeks).

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

14

Conclusion
In the current hospital setting, the use of oral dextrose gel in addition to oral feedings was
superior to treating NH as compared to oral feedings alone. The protocol created will be shared
with other facilities, and larger studies need to be done to see if results are generalizable.
Additionally, more research needs to be done to include small community or outlying hospitals
that do not have NICUs, to see if the incorporation of oral dextrose gel in their existing NH
protocols in newborn nurseries can also decrease the need for patient transfer to other hospitals
for higher level of care in this particular population.

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

15

References
Bennett, C., Fagan, E., Chaharbakhshi, E., Zamfirova, I., & Flicker, J. (2016). Implementing a
protocol using glucose gel to treat neonatal hypoglycemia. Nursing for Women's Health,
20(1), 64-74. doi:10.1016/j.nwh.2015.11.001
Bennett, C., Headtke, E., & Rowe‐Telow, M. (2015). Use of dextrose gel reverses neonatal
hypoglycemia and decreases admissions to the NICU. Journal of Obstetric, Gynecologic,
& Neonatal Nursing, 44(s1), S52-S53. doi:10.1111/1552-6909.12614
Brown, L., & Rozance, P. (2016). A sweet addition for the treatment of neonatal hypoglycemia.
Journal of Pediatrics, 170, 10-12. doi:10.1016/j.jpeds.2015.12.036
Committee on Fetus and Newborn & Adamkin, D. H. (2011). Postnatal glucose homeostasis in
late-preterm and term infants. Pediatrics, 127(3), 575–579. doi:10.1542/peds.2010-3851
Harding, J., Hegarty, J., Crowther, C., Edlin, R., Gamble, G., & Alsweiler, J. (2015).
Randomised trial of neonatal hypoglycaemia prevention with oral dextrose gel (hPOD):
Study protocol. BMC Pediatrics, 15(1), 120. doi:10.1186/s12887-015-0440-6
Harris, D. L., Weston, P. J., & Harding, J. E. (2012). Incidence of neonatal hypoglycemia in
babies identified as at risk. The Journal of Pediatrics, 161(5), 787-791.
doi:10.1016/j.jpeds.2012.05.022
Harris, D., Weston, P., Signal, M., Chase, J., & Harding, J. (2013). Dextrose gel for neonatal
hypoglycaemia (the sugar babies study): A randomised, double-blind, placebo-controlled
trial. Lancet, 382(9910), 2077-2083. doi:10.1016/S0140-6736(13)61645-1
Hegarty, J., Harding, J., Gamble, G., Crowther, C., Edlin, R., & Alsweller, J. (2016).
Prophylactic oral dextrose gel for newborn babies at risk of neonatal hypoglycaemia:

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL

16

A randomised controlled dose-finding trial (the pre-hPOD study). PLOS Medicine,
13(10), e1002155. doi:10.1371/journal.pmed.1002155
IBM Corp. (2016). IBM SPSS Statistics for Macintosh, Version 24.0. Armonk, NY: IBM Corp.
Ly, E., Alexander, J., Akinmboni, T., Woo, H., & Driscoll, C. (2016). Improving the diagnosis of
neonatal hypoglycemia in a well-baby nursery. BMJ Quality Improvement Reports, 5(1),
u214381.w5806. doi:10.1136/bmjquality.u214381.w5806
March of Dimes Perinatal Data Center (2011). Special care nursery admissions. Retrieved from
https://www.marchofdimes.org/peristats/pdfdocs/nicu_summary_final.pdf
Melnyk, B., & Fineout-Overholt, E. (2015). Evidence-based practice in nursing &
healthcare (3rd ed.). Philadelphia, PA: Wolters Kluwer Health.
Mosalli, R. (2014). Dextrose gel is superior to feeding alone in neonatal hypoglycemia. Journal
of Clinical Neonatology, 3(1), 10.
Rawat, M., Chandrasekharan, P., Turkovich, S., Barclay, N., Perry, K., Schroeder, E., . . .
Lakshminrusimha, S. (2016). Oral dextrose gel reduces the need for intravenous dextrose
therapy in neonatal hypoglycemia. Biomedicine Hub, , 1-9. doi:10.1159/000448511
Rosswurm, M., & Larrabee, J. (1999). A model for change to evidence-based practice. Journal
of Nursing Scholarship, 31(4), 317-322. doi:10.1111/j.1547-5069.1999.tb00510.x
Shirey, M. (2013). Lewin's Theory of Planned Change as a strategic resource. The Journal of
Nursing Administration, 43(2), 69-72.
Simmons, R., & Stanley, C. (2015). Neonatal hypoglycemia studies - is there a sweet story of
success yet? New England Journal of Medicine, 373(16), 1567-1569.
doi:10.1056/NEJMe1511994

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Weston, P. J., Harris, D. L., Battin, M., Brown, J., Hegarty, J. E., & Harding, J. E. (2016). Oral
dextrose gel for the treatment of hypoglycaemia in newborn infants. The Cochrane
Database of Systematic Reviews, 2016(5), CD011027.
doi:10.1002/14651858.CD011027.pub2

17

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Appendix A
Search Strategy 1: Cochrane Library

18

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Appendix B
Search Strategy 2: PubMed

19

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Appendix C
Search Strategy 3: EBSCOhost CINAHLplus with full text

20

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Appendix D
Search Strategy 4: ASU Libraries OneSearch

21

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Appendix E
Model for Evidence-Based Practice Change (Rosswurm & Larrabee, 1999)

22

NEONATAL HYPOGLYCEMIA AND THE ROLE OF ORAL DEXTROSE GEL
Appendix F
Neonatal Hypoglycemia Algorithm

23